References
- Anastasiadis E, van der Meulen J, Emberton M (2014). Hospital admissions after TRUS biopsy of the prostate in men diagnoses with prostate cancer: A database analysis in England. Int J Urol, 22, 101-6.
- Beach R, Gown AM, Peralta-Venturina MN, et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol, 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
- Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy, 1, 377-88 https://doi.org/10.1080/0032472031000141283
- Campbell MF, Wein AJ, Kavoussi LR (2011). Campbell's Urology 2011. V, Section II, chapter 3.
- Carlson GD, Calvanese CB, Partin AW (1998). An algorithm combining age, total PSA and percent free PSA to predict prostate cancer: results in 4298 cases. Urol, 52, 455-461 https://doi.org/10.1016/S0090-4295(98)00205-2
- Chun FK, Briganti A, Graefen M, et al (2007). Development and external validation of an extended repeat biopsy nomogram. J Urol, 177, 510-5. https://doi.org/10.1016/j.juro.2006.09.025
- Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91. https://doi.org/10.1016/j.juro.2008.01.102
- Djavan B, Zlotta A, Remzi M, et al (2000). Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol, 163, 1144-8. https://doi.org/10.1016/S0022-5347(05)67711-7
- Djavan B, Remzi M, Zlotta A, et al (2002). Novel artificial neural network for early detection of prostate cancer. J Clin Oncol, 20, 921-9. https://doi.org/10.1200/JCO.2002.20.4.921
- Eschwege P, Moutereau S, Droupy S, et al (2009). Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer, 100, 608-10. https://doi.org/10.1038/sj.bjc.6604912
- Eggener SE, Roehl KA, Catalona WJ (2005). Predictors of subsequent prostate cancer in men with a PSA of 2.6-4.0ng/ml and an initially negative prostate biopsy. J Urol, 174, 500-4. https://doi.org/10.1097/01.ju.0000165203.40973.0f
- Epstein JI, Walsh PC, Carmichael M, et al (1994), Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271, 368-374. https://doi.org/10.1001/jama.1994.03510290050036
- Fizazi K, Morat L, Chauveinc L, et al (2007). High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol, 18, 518-21.
- Fowler JE Jr, Bigler SA, Miles D, et al (2000). Predictors of the first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol, 163, 813-8. https://doi.org/10.1016/S0022-5347(05)67810-X
- Graham J, Baker M, Macbeth F, et al (2008). Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ, 336, 610-2. https://doi.org/10.1136/bmj.39498.525706.AD
- Lopez E, Ohori M, Scardino PT, et al (2003). A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative seesion. J Urol, 170, 1184-88. https://doi.org/10.1097/01.ju.0000087451.64657.fa
- Moreno JG, Croce CM, Fischer R, et al (1992) Detection of hemato¬genous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2.
- Murray NP, Reyes E, Badinez L, et al (2013). Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications. J Oncol, 2013.
- Murray NP, Reyes E, Orellana N, et al (2013a). Cost benefit of the use of circulating prostate cells to detect prostate cancer. Arch Esp Urol, 66, 277-86.
- Murray NP, Reyes E, Orellana N, et al (2014). A comparative performance analysis of Total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. Bio Med Research Int.
- Murray NP, Reyes E, Fuentealba C, et al (2014a). Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer. J Oncol.
- Panteleakou Z, Lembessis P. Sourla A, et al (2009). Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls andclinical relevance. Mol Med, 15, 101-14.
- Paterlini-Brechot P and Benali NL (2007). Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters, 253, 180-204. https://doi.org/10.1016/j.canlet.2006.12.014
-
Pavlakis K, Stravodimos K, Kapetanakis T, et al (2010) Evaluation of routine applications of P504S,
$34{\beta}E12$ and p63 immunostaining on 250 prostate needle biopsy specimens. Int Urol Nephrol, 42, 325-30. https://doi.org/10.1007/s11255-009-9622-1 - Raimondi C, Gradilone A, Naso G, et al (2011). Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat, 130, 449-55. https://doi.org/10.1007/s10549-011-1373-x
- Rodriguez LV, Terris Mk (1998). Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literatura. J Urol, 160, 2115-20. https://doi.org/10.1016/S0022-5347(01)62255-9
- Rubin MA, Zhou M, Dhanasekaran SM, et al (2001). alphamethylacyl Coenzyme-A racemase as a tissue biomarker for prostate cancer. JAMA, 287, 1662-70.
- Shariat SF, Karakiewicz PI, Roehrborn CG, et al (2008). An updated catalog of prostate cancer predictive tools. Cancer,